Raymond James Financial Inc. Purchases New Holdings in Haemonetics Co. (NYSE:HAE)

Raymond James Financial Inc. purchased a new stake in Haemonetics Co. (NYSE:HAE) in the fourth quarter, HoldingsChannel reports. The firm purchased 243,364 shares of the medical instruments supplier’s stock, valued at approximately $19,002,000.

A number of other hedge funds and other institutional investors have also modified their holdings of HAE. Wellington Management Group LLP grew its holdings in Haemonetics by 9.5% during the 3rd quarter. Wellington Management Group LLP now owns 4,201,565 shares of the medical instruments supplier’s stock worth $337,722,000 after acquiring an additional 363,702 shares during the period. Geode Capital Management LLC grew its holdings in Haemonetics by 1.8% during the 3rd quarter. Geode Capital Management LLC now owns 1,193,927 shares of the medical instruments supplier’s stock worth $95,986,000 after acquiring an additional 21,547 shares during the period. Thrivent Financial for Lutherans grew its holdings in Haemonetics by 29.5% during the 3rd quarter. Thrivent Financial for Lutherans now owns 1,100,183 shares of the medical instruments supplier’s stock worth $88,433,000 after acquiring an additional 250,833 shares during the period. Boston Trust Walden Corp grew its holdings in Haemonetics by 13.1% during the 4th quarter. Boston Trust Walden Corp now owns 915,722 shares of the medical instruments supplier’s stock worth $71,500,000 after acquiring an additional 106,114 shares during the period. Finally, Westfield Capital Management Co. LP grew its holdings in Haemonetics by 10.9% during the 3rd quarter. Westfield Capital Management Co. LP now owns 823,663 shares of the medical instruments supplier’s stock worth $66,206,000 after acquiring an additional 80,783 shares during the period. Institutional investors and hedge funds own 99.67% of the company’s stock.

Haemonetics Trading Down 0.3 %

HAE opened at $65.76 on Monday. The stock has a market capitalization of $3.30 billion, a P/E ratio of 25.89, a P/E/G ratio of 1.11 and a beta of 0.43. Haemonetics Co. has a 12 month low of $58.80 and a 12 month high of $97.97. The firm’s fifty day simple moving average is $68.61 and its 200 day simple moving average is $75.41. The company has a current ratio of 3.97, a quick ratio of 2.55 and a debt-to-equity ratio of 1.35.

Haemonetics (NYSE:HAE) last posted its quarterly earnings data on Thursday, February 6th. The medical instruments supplier reported $1.19 EPS for the quarter, missing the consensus estimate of $1.20 by ($0.01). Haemonetics had a net margin of 9.47% and a return on equity of 23.66%. As a group, research analysts anticipate that Haemonetics Co. will post 4.55 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of analysts have commented on HAE shares. JPMorgan Chase & Co. started coverage on shares of Haemonetics in a report on Friday, December 6th. They set an “overweight” rating and a $116.00 target price for the company. JMP Securities reduced their price target on shares of Haemonetics from $125.00 to $100.00 and set a “market outperform” rating on the stock in a research report on Friday, February 7th. Needham & Company LLC reduced their price target on shares of Haemonetics from $112.00 to $108.00 and set a “buy” rating on the stock in a research report on Friday, February 7th. Barrington Research reduced their price target on shares of Haemonetics from $108.00 to $95.00 and set an “outperform” rating on the stock in a research report on Friday, February 7th. Finally, Raymond James reissued a “strong-buy” rating and set a $115.00 price target (down from $120.00) on shares of Haemonetics in a research report on Friday, February 7th. One analyst has rated the stock with a sell rating, two have issued a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $101.67.

Haemonetics Company Profile

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app.